Clinical Trial

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
Protocol Amendment History 55 amendments
This ClinicalTrials.gov record has been amended 55 times since 2023-08-03; most recent amendment 2026-02-12.
Status change: Recruiting → Active, Not Recruiting 2026-02-12
Status change: Not Yet Recruiting → Recruiting 2023-08-14
Trial Details
NCT Number NCT05987332
Lead Sponsor IDEAYA Biosciences
Conditions Metastatic Uveal Melanoma
Enrollment 420 participants
Start Date 2023-10-31
Primary Completion 2027-01-15 (estimated)
Study Completion 2028-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-17